Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

This study will test the safety and tolerability (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in healthy subjects. The study drug and placebo will be administered by an injection under the skin at one clinic visit. There will be 14 clinic visits, which will include 4 overnight stays. Subjects will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs (blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.

Key facts

Study ID

NCT01074372

Run by

Regeneron Pharmaceuticals

People needed

32

Starts

2010-03-01

Expected to finish

2010-11-01

Last updated by the study team

2015-01-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female 18 to 65 years of age.
• Weight> 50 kg and <95 kg inclusive
• For women of childbearing potential, a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day 1.
• For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner[s] become pregnant during the full duration of the study.
• Willing, committed, and able to return for all clinic visits and complete all study-related procedures.
• Able to read, understand and willing to sign the informed consent form.

You may not qualify if…

• Initiation of a new exercise routine or major change to a previous exercise routine within 4 weeks prior to screening visit.
• Pregnant or breast-feeding females.
• Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the subject's participation in this study.
• Hospitalization for any reason within 60 days of screening.
• Known history of Human Immunodeficiency Virus (HIV) antibody; and/or positive Hepatitis B surface antigen, and/or positive Hepatitis C antibody at the screening visit.
• Previous exposure to any therapeutic or investigational biological agent.
• History of alcohol or substance abuse within previous 5 years.

Where it is running

• Study site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.